07:00 , Jun 28, 2010 |  BC Week In Review  |  Company News

Takeda sales and marketing update

Takeda's Takeda Pharmaceuticals North America Inc. subsidiary launched ACTOplus met XR extended-release pioglitazone/metformin tablets in the U.S. to treat Type II diabetes. The once-daily fixed-dose combination of a peroxisome proliferation activated receptor (PPAR)...
07:00 , May 18, 2009 |  BC Week In Review  |  Clinical News

ACTOplus met XR pioglitazone/extended-release metformin regulatory update

FDA approved extended-release ACTOplus met XR to treat Type II diabetes in adults already receiving Actos pioglitazone and metformin or who have inadequate glycemic control on Actos or metformin alone. Once-daily ACTOplus met XR...
07:00 , Apr 10, 2006 |  BC Week In Review  |  Clinical News

ACTOplus met XR regulatory update

Takeda submitted an NDA for once-daily ACTOplus met XR, an extended-release version of ACTOplus met, to treat Type II diabetes. The application was submitted on March 31. ACTOplus met, which was approved by FDA last...